Equities Analysts Offer Predictions for TSE:BHC Q3 Earnings

Bausch Health Companies Inc. (TSE:BHC - Free Report) - Analysts at Zacks Research raised their Q3 2026 earnings estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Friday, July 24th. Zacks Research analyst Team now forecasts that the company will post earnings of $1.47 per share for the quarter, up from their previous estimate of $1.42. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q2 2027 earnings at $1.16 EPS, Q3 2027 earnings at $1.47 EPS, Q4 2027 earnings at $1.33 EPS, FY2027 earnings at $5.10 EPS, Q1 2028 earnings at $0.81 EPS, Q2 2028 earnings at $1.16 EPS and FY2028 earnings at $4.34 EPS.

Bausch Health Companies (TSE:BHC - Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported C$1.08 earnings per share for the quarter. The business had revenue of C$3.51 billion for the quarter. Bausch Health Companies had a negative net margin of 13.54% and a positive return on equity of 120.43%.

Separately, Jefferies Financial Group raised shares of Bausch Health Companies to a "hold" rating in a research note on Wednesday, July 22nd. Three research analysts have rated the stock with a Hold rating, According to MarketBeat, Bausch Health Companies presently has a consensus rating of "Hold".

Bausch Health Companies Trading Up 1.4%

Shares of BHC stock opened at C$6.34 on Tuesday. The company has a market capitalization of C$2.37 billion, a P/E ratio of -1.96, a P/E/G ratio of 0.21 and a beta of 0.97. Bausch Health Companies has a 12-month low of C$6.10 and a 12-month high of C$11.97. The company has a quick ratio of 0.58, a current ratio of 1.32 and a debt-to-equity ratio of -1,009.96. The firm has a 50-day moving average price of C$7.00 and a 200 day moving average price of C$7.63.

Bausch Health Companies Company Profile

Bausch Health Companies Inc NYSE: BHCTSX: BHC is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.